We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
-$263M
Cap. Flow
-$30.3M
Cap. Flow %
-2.33%
Top 10 Hldgs %
46.95%
Holding
119
New
12
Increased
27
Reduced
37
Closed
33

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$41.1M
2
MASI
Masimo
MASI
+$40.1M
3
GSK icon
GSK
GSK
+$30.1M
4
HCA icon
HCA Healthcare
HCA
+$15.7M
5
RCM
R1 RCM Inc. Common Stock
RCM
+$15.4M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$22.8M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.8M
3
UTHR icon
United Therapeutics
UTHR
+$19M
4
NVST icon
Envista
NVST
+$12.9M
5
HUM icon
Humana
HUM
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 78.97%
2 Miscellaneous 18.23%
3 Industrials 2.8%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBYI icon
51
Puma Biotechnology
PBYI
$468M
$4.1M 0.32%
1,424,650
+306,752
+27% +$793K
MRK icon
52
CALL
Merck
MRK
$366B
$4M 0.31%
48,700
– –
GOSS icon
53
Gossamer Bio
GOSS
$83.2M
$3.25M 0.25%
374,723
+334,813
+839% +$3.23M
VRDN icon
54
Viridian Therapeutics
VRDN
$2.61B
$2.88M 0.22%
155,743
-38,846
-20% -$746K
ANAB icon
55
AnaptysBio
ANAB
$1.67B
$2.82M 0.22%
114,165
-68,447
-37% -$2.07M
RDUS
56
DELISTED
Radius Health, Inc.
RDUS
$2.67M 0.2%
+302,172
New +$2.29M
PGNY icon
57
PUT
Progyny
PGNY
$1.99B
$2.57M 0.2%
50,000
– –
WHWK
58
Whitehawk Therapeutics
WHWK
$263M
$2.56M 0.2%
+150,817
New +$2.89M
A icon
59
Agilent Technologies
A
$43.4B
$2.55M 0.2%
19,255
-176
-0.9% -$24.2K
ISRG icon
60
Intuitive Surgical
ISRG
$132B
$2.46M 0.19%
8,163
-1,662
-17% -$486K
MRUS
61
DELISTED
Merus
MRUS
$2.03M 0.16%
76,849
+57,849
+304% +$1.55M
KRTX
62
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$2.02M 0.16%
15,934
– –
MRK icon
63
Merck
MRK
$366B
$1.99M 0.15%
9,483
-9,973
-51% -$786K
RVTY icon
64
Revvity
RVTY
$14.4B
$1.71M 0.13%
9,788
-21,081
-68% -$3.75M
AUTL
65
Autolus Therapeutics
AUTL
$623M
$1.55M 0.12%
371,540
-30,000
-7% -$126K
KOD icon
66
PUT
Kodiak Sciences
KOD
$2.37B
$1.4M 0.11%
+181,200
New +$7.07M
MIST icon
67
Milestone Pharmaceuticals
MIST
$144M
$945K 0.07%
147,165
– –
ENSG icon
68
The Ensign Group
ENSG
$10.1B
$936K 0.07%
10,397
– –
TEVA icon
69
CALL
Teva Pharmaceuticals
TEVA
$42.5B
$872K 0.07%
92,900
-869,500
-90% -$7.26M
HSKA
70
DELISTED
Heska Corp
HSKA
$807K 0.06%
5,836
+1,311
+29% +$185K
KOD icon
71
Kodiak Sciences
KOD
$2.37B
$704K 0.05%
+91,200
New +$3.56M
ASMB icon
72
Assembly Biosciences
ASMB
$694M
$577K 0.04%
23,333
-2,500
-10% -$53.7K
SPRO icon
73
Spero Therapeutics
SPRO
$69.9M
$519K 0.04%
+59,639
New +$611K
SNDA icon
74
Sonida Senior Living
SNDA
$1.8B
$504K 0.04%
15,209
– –
ACIU icon
75
AC Immune
ACIU
$263M
$498K 0.04%
124,589
-28,791
-19% -$125K
1 2
3
4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2022 Portfolio in Review

As of Q1 2022, Eversept Partners held 119 positions worth $1.3B, down 17% from $1.57B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners's Q1 2022 filing shows 12 new, 27 increased, 37 reduced and 33 closed positions. Its largest new stake was Masimo: 208,970 shares worth $30.4M. The largest sale was McKesson, an estimated $22.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 72% a quarter earlier, followed by Miscellaneous and Industrials.

  • Eversept Partners's largest Q1 2022 buy was Masimo: 208,970 shares worth $30.4M.
  • Eversept Partners added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2022, an estimated $41.1M increase.
  • Eversept Partners's biggest Q1 2022 reduction was McKesson, cutting an estimated $22.8M.
  • Eversept Partners fully exited Humana in Q1 2022, selling an estimated $12.7M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.3B portfolio in Q1 2022.
  • Eversept Partners opened 12 new positions and closed 33 in Q1 2022.
  • Eversept Partners's portfolio value fell 17% quarter-over-quarter to $1.3B.

Based on Eversept Partners's 13F filing for Q1 2022, filed 16 May 2022.